Zevra Therapeutics (ZVRA) Net Income towards Common Stockholders (2016 - 2025)
Historic Net Income towards Common Stockholders for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to -$544000.0.
- Zevra Therapeutics' Net Income towards Common Stockholders rose 9836.27% to -$544000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $35.3 million, marking a year-over-year increase of 13939.71%. This contributed to the annual value of -$105.5 million for FY2024, which is 12912.77% down from last year.
- Zevra Therapeutics' Net Income towards Common Stockholders amounted to -$544000.0 in Q3 2025, which was up 9836.27% from $74.7 million recorded in Q2 2025.
- In the past 5 years, Zevra Therapeutics' Net Income towards Common Stockholders registered a high of $74.7 million during Q2 2025, and its lowest value of -$47.7 million during Q1 2021.
- Its 5-year average for Net Income towards Common Stockholders is -$9.7 million, with a median of -$10.4 million in 2023.
- Per our database at Business Quant, Zevra Therapeutics' Net Income towards Common Stockholders plummeted by 134505.24% in 2021 and then skyrocketed by 47494.1% in 2025.
- Quarter analysis of 5 years shows Zevra Therapeutics' Net Income towards Common Stockholders stood at -$2.7 million in 2021, then tumbled by 233.74% to -$9.0 million in 2022, then crashed by 120.51% to -$19.9 million in 2023, then crashed by 79.67% to -$35.7 million in 2024, then skyrocketed by 98.48% to -$544000.0 in 2025.
- Its last three reported values are -$544000.0 in Q3 2025, $74.7 million for Q2 2025, and -$3.1 million during Q1 2025.